Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  pemetrexed disodium
Find trials that include:  Any drugs shown
Results 1-25 of 45 for your search:
Start Over
Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer
Phase: Phase III, Phase II
Type: Treatment
Age: 18 and over
Trial IDs: NLG0301, NCI-2013-00592, 1209-1184, NCT01774578
LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CLDK378A2303, NCI-2014-00520, 2012-005637-36, NCT01828112
Nintedanib (BIBF 1120) in Mesothelioma
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 1199.93, NCI-2013-01643, 2012-005201-48, NCT01907100
A Comparative Study of Atezolizumab (MPDL3280A) With Cisplatin or Carboplatin + Pemetrexed in Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110]
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GO29431, NCI-2015-01580, 2014-003083-21, NCT02409342
Intensity-Modulated Radiation Therapy, Pemetrexed Disodium, and Erlotinib Hydrochloride in Treating Patients With Recurrent or Second Primary Head and Neck Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CCCWFU 60107, NCI-2009-01250, CCCWFU-IRB00003457, CDR0000578838, LILLY-CCCWFU-60107, NCT01580449, P30CA012197, NCT00573989
Panobinostat and Pemetrexed Disodium in Treating Patients With Previously Treated Advanced Non-Small Cell Lung Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 08-036, NCI-2011-02483, NCT00907179
Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma
Phase: Phase II, Phase I
Type: Tissue collection/Repository, Treatment
Age: 18 and over
Trial IDs: S0905, NCI-2011-02015, CDR0000665415, SWOG-S0905, NCT01064648
A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Lung Cancer (MK-3475-021/KEYNOTE-021)
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 3475-021, NCI-2014-00482, NCT02039674
Pemetrexed Disodium or Observation in Treating Patients with Malignant Pleural Mesothelioma without Progressive Disease after First-Line Chemotherapy
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: CALGB 30901, NCI-2011-02023, CDR0000667496, NCT01085630
GSK1120212 Rollover Study
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 114375, NCI-2011-03211, NCT01376310
Afatinib Dimaleate, Combination Chemotherapy, and Radiation Therapy in Treating Patients with Stage III Non-small Cell Lung Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 11-464, NCI-2012-01535, 1200.158, NCT01553942
Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer
Phase: Phase II
Type: Treatment
Age: 18 to 75
Trial IDs: INCB 18424-266, NCI-2014-01067, NCT02119650
Pemetrexed Disodium with or without Crizotinib in Treating Patients with Stage IV Non-small Cell Lung Cancer That Has Progressed after Treatment with Crizotinib Alone
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: S1300, NCI-2014-00685, NCT02134912
Cisplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation before Surgery in Treating Patients with Stage IIIA Non-small Cell Lung Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: LCCC 1407, NCI-2015-00192, 14-2146, NCT02276560
Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Pleural Mesothelioma (MPM).
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MORAb-009-201, NCI-2015-01754, NCT02357147
A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLC
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MM-121-01-02-09, NCI-2015-00560, NCT02387216
Pemetrexed Disodium in Treating Patients with Stage IV Non-small Cell Lung Cancer and ECOG Performance Status 3
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CCCWFU # 62115, NCI-2015-00596, NCT02426658
Start Over